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Neuropathic pain is often insensitive to morphine. Our previous study has demonstrated that neuron-
restrictive silencer factor represses mu opioid receptor (MOP) gene expression in the dorsal root gan-
glion (DRG) via histone hypoacetylation-mediated mechanisms after peripheral nerve injury, thereby
causing loss of peripheral morphine analgesia. Here, we showed that histone deacetylase (HDAC) in-
hibitors, such as trichostatin A and valproic acid, restored peripheral and systemic morphine analgesia in
neuropathic pain. Also, these agents blocked nerve injury-induced MOP down-regulation in the DRG.
These results suggest that HDAC inhibitors could serve as adjuvant analgesics to morphine for the
management of neuropathic pain.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Neuropathic pain is manifested by combination of positive
(hyperalgesia and allodynia) and negative (hypoesthesia and
hypoalgesia) symptoms (1). Patients with neuropathic pain are
often insensitive to conventional analgesics, including morphine
(2). Also, the morphine resistance has been observed in diverse
animal models of neuropathic pain caused by peripheral nerve
injury (3), post-herpetic neuralgia (4), and bone cancer (5). Under
thesemodels, the common event is a down-regulation of mu opioid
receptor (MOP) expression in the dorsal root ganglion (DRG) (3e5).
Accordingly, previous studies have shown that the intraplantarly
administrated morphine fails to produce analgesic effects on
neuropathic pain (3), and that injury reduces the pre-synaptic
inhibitory action of MOP agonist (6). Therefore, the elucidation of
mechanisms underlying MOP down-regulation after injury could
be important to overcome the morphine resistance in neuropathic
pain.
Neuron-restrictive silencer factor (NRSF, also known as
repressor element-1 silencing transcription factor) represses tran-
scription of neuron-restrictive silencer element (NRSE)-containing
genes via recruitment of histone deactylase (HDAC) enzymes
through co-repressors, mSin3 and CoREST (7). Our previous study: þ81 95 819 2420.
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d/4.0/).has demonstrated that NRSF causes injury-induced morphine
resistance and hypoesthesia by histone hypoacetylation-mediated
silencing of NRSE-containing MOP and sodium channel Nav1.8
genes, respectively (8). We have also reported that HDAC inhibitors,
such as trichostatin A (TSA) and valproic acid (VPA), block injury-
induced Nav1.8 down-regulation in the DRG and hence improve
hypoesthesia (9); yet, the functional involvement of HDAC in
morphine resistance remains to be investigated. Thus, we tested
here whether HDAC inhibitors could block injury-induced MOP
down-regulation, thereby relieving the morphine resistance.
Male C57BL/6J mice weighing 20e25 g were used. They were
kept in a roomwith a temperature of 21 ± 2 C with free access to a
standard laboratory diet and tap water. All experimental pro-
cedures were approved by the Nagasaki University Animal Care
Committee, and complied with the fundamental guidelines for the
proper conduct of animal experiments and related activities in
academic research institutions under the jurisdiction of the Min-
istry of Education, Culture, Sports, Science and Technology, Japan.
Partial ligation of the sciatic nerve was performed as described
previously (8).
TSA (Wako Pure Chemical Industries, Ltd., Osaka) dissolved in
10% ethanol in physiological saline and VPA sodium salt (Sigma-
eAldrich, St. Louis, MO, USA) dissolved in physiological saline were
intraperitoneally injected 60 min and 120 min prior to injury,
respectively, and once daily post-injury. Analgesic tests were per-
formed 60 min or 120 min after the last treatment of TSA or VPA,nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 2. Prevention of injury-induced loss of systemic morphine analgesia by HDAC
inhibitors. TSA (1 mg/kg, i.p.) or VPA (200 mg/kg, i.p.) was administrated 60 min or
120 min prior to injury, respectively, and once daily for 3 days after nerve injury.
Thermal pain threshold was assessed at day 3 post-injury, using a thermal paw
withdrawal test. A and B) Time-courses of thermal paw-withdrawal latencies (PWL, in
seconds) after morphine (1 mg/kg, s.c.) injection in sham-operated mice (A) and nerve-
injured mice (B). *P < 0.05, vs. vehicle (Veh)-treated group. C and D) Comparison of
morphine analgesia after TSA (C) and VPA (D) treatments by area under the curve
(AUC). *P < 0.05, vs. Veh-treated and sham-operated group and #P < 0.05, vs. Veh-
treated and nerve-injured group. Data are expressed as the means ± SEM from at
least ﬁve mice.
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Osaka) dissolved in physiological saline was injected intraplantarly
or subcutaneously. To assess morphine analgesia, the area under
the curve was measured by trapezoidal rule with subtraction of the
basal value at 0 min from the value for each withdrawal threshold
from 10 to 60 min after morphine treatment.
In thermal paw withdrawal tests, the latency to withdrawal
from a thermal stimulus (IITC Inc., Woodland Hills, CA, USA) was
assessed as a nociception threshold, as described previously (8). A
cut-off time of 20 s was set to prevent tissue damage.
We collected L4-6 DRGs just after analgesic tests. The extraction
of total RNA from L4-6 DRGs, cDNA synthesis, and real-time PCR
using gene-speciﬁc primers were performed as described previ-
ously (8). Glyceraldehyde-3-phosphate dehydrogenase was used as
an internal control for normalization.
Statistical analyses of results were performed using Student's t-
test or a one-way ANOVAwith TukeyeKramermultiple comparison
post hoc test. The criterion of signiﬁcance was set at P < 0.05. All
results were expressed as means ± SEM.
Firstly, we conﬁrmed that a single intraperitoneal (i.p.) admin-
istration of TSA (1mg/kg) elevated histone H3 and H4 acetylation in
the DRG at least 60 min post-injection (data not shown). To
examine whether HDAC inhibitor could relieve the loss of periph-
eral morphine analgesia after injury, mice were given repeated i.p.
injections of TSA (1 mg/kg) for 7 days, starting from 60 min prior to
injury. Consistent with previous report (9), neither the basal noci-
ceptive threshold in sham-operated mice nor thermal pain hyper-
sensitivity in nerve-injured mice was affected by TSA (Fig. 1: A, B).
Meanwhile, a lack of analgesic action of intraplantarly injected
morphine (30 nmol) was remarkably recovered by TSA (Fig. 1: B, C).
In contrast, TSA had no effects on peripheral morphine analgesia in
sham-operated mice (Fig. 1: A, C).
Next, we assessed whether HDAC inhibitors could restore the
systemic morphine analgesia after injury. Mice were treated with
subcutaneous (s.c.) injections of morphine at a dose of 1 mg/kg that
fails to produce analgesia in nerve-injured mice (3). The loss of
systemic morphine analgesia at day 3 post-injury was recovered by
TSA (Fig. 2: AeC). In addition to TSA, we used VPA, another HDAC
inhibitor, at a dose of 200 mg/kg that exerts no anti-hyperalgesic
action (10) but blocks injury-induced Nav1.8 down-regulation in
the DRG (9). Repeated i.p. treatments with VPA also restored the
systemic morphine analgesia in nerve-injured mice (Fig. 2D).
Moreover, VPA signiﬁcantly improved the sensitivity to peripher-
ally injected morphine, but not thermal hyperalgesia, after injury
(data not shown). In contrast, both HDAC inhibitors had no effectsFig. 1. Blockade of injury-induced loss of peripheral morphine analgesia by TSA. TSA (1 mg/
injury. Thermal pain threshold was assessed at day 7 post-injury, using a thermal paw w
seconds) after intraplantar injection of morphine (30 nmol) in sham-operated mice (A) an
morphine analgesia by area under the curve (AUC). *P < 0.05, vs. Veh-treated and sham-oper
as the means ± SEM from at least ten mice.on the systemic morphine analgesia in sham-operated mice (Fig. 2:
A, C, D).
To test whether HDAC inhibitors could block injury-induced
MOP down-regulation, we isolated L4-6 DRGs at day 3 post-
injury, and mRNA expression levels were quantiﬁed by real-time
PCR. Injury-induced reduction of MOP mRNA expression was
signiﬁcantly recovered by treatments with TSA and VPA (Fig. 3: A,
B). In contrast, these agents had no effects on MOP expression in
sham-operated mice, in agreement with the behavioural data
(Fig. 2).kg, i.p.) was administrated 60 min prior to injury and once daily for 7 days after nerve
ithdrawal test. A and B) Time-courses of thermal paw-withdrawal latencies (PWL, in
d nerve-injured mice (B). *P < 0.05, vs. vehicle (Veh)-treated group. C) Comparison of
ated group and #P < 0.05, vs. Veh-treated and nerve-injured group. Data are expressed
Fig. 3. Blockade of injury-induced MOP down-regulation by HDAC inhibitors. TSA
(1 mg/kg, i.p.) or VPA (200 mg/kg, i.p.) was administrated 60 min or 120 min prior to
injury, respectively, and once daily for 3 days after nerve injury. A and B) The effects of
TSA (A) and VPA (B) on nerve injury-induced down-regulations of MOP mRNA in the
DRG at day 3 post-injury. The mRNA expression levels were quantiﬁed by real-time
PCR, and normalized to that of GAPDH mRNA. Results are calculated as percentages
of vehicle (Veh)-treated and sham-operated group, and expressed as means ± SEM
from at least eight mice. *P < 0.05, vs. Veh-treated and sham-operated group and
#P < 0.05, vs. Veh-treated and nerve-injured group.
H. Uchida et al. / Journal of Pharmacological Sciences 128 (2015) 208e211210NRSF is known to target MOP gene that contains NRSE sequence
around its initial codon (11). In neuronal cells, NRSF-mediated
repression of MOP expression is sensitive to TSA, suggesting that
HDAC is needed for silencing of MOP gene via NRSF (11). Previously,
we have demonstrated that injury up-regulates NRSF expression in
the DRG, concomitantly with an increase of NRSF binding to
MOPeNRSE and a decrease in histone acetylation at the same site
(8). Importantly, antisense knockdown of NRSF blocks injury-
induced MOP down-regulation in the DRG, indicating a causal
role of NRSF (8). Here, we showed that injury-induced MOP down-
regulation was recovered by the treatments with HDAC inhibitors.
However, these agents were unable to affect MOP expression in the
sham-operatedmice, in agreement with the ﬁndings obtained from
antisense-mediated NRSF knockdown (8). These ﬁndings suggest
that injury could initiate HDAC-mediated mechanisms underlying
MOP down-regulation in the DRG, possibly inducing NRSF
expression. Based on the evidence that TSA has no effects on NRSF
expression in neuronal cells (11) and that injury-induced NRSF up-
regulation in the DRG is insensitive to HDAC inhibitor sub-
eroylanilide hydroxamic acid (9), it is unlikely that HDAC inhibitors
prevent injury-inducedMOP down-regulation via blockade of NRSF
induction in the DRG. On the other hand, NRSF has been known to
preferentially recruit HDAC1 and HDAC2 via mSin3 and CoREST (7).
Previous study has shown that transcription factor Sp3 binds to GC-
box adjacent to MOPeNRSE and interacts with NRSF and HDAC2,
but not HDAC1, to synergistically repress MOP transcription (12).
Further studies are required to identify the HDAC subtypes involved
in NRSF-mediated silencing of MOP transcription after injury. Also,
whether HDAC inhibitors restore MOP expression after injury via
blockade of NRSFeSp3eHDAC2-mediated epigenetic mechanisms
is the subject of future research.
Previously, we have shown that subcutaneously, intraplantarly
and intrathecally, but not intracerebroventricularly, administrated
morphine exert diminished analgesic effects after injury (3), sug-
gesting that the impairments of peripheral and spinal morphine
actions are responsible for the reduced efﬁcacy of systemic
morphine. Accordingly, electrophysiological study has revealed
that injury reduces spinal pre- and post-synaptic actions of MOP
agonist (6). Importantly, mice lacking G protein-coupled inwardly
rectifying potassium channel 2, a major post-synaptic effector of
morphine, show signiﬁcant residual morphine analgesia, implyinga critical contribution of pre-synaptic morphine action to its anal-
gesic effect (13). Given that HDAC inhibitors blocked injury-induced
MOP down-regulation in the DRG, it is conceivable that HDAC in-
hibitors could ameliorate peripheral and spinal pre-synaptic ac-
tions of morphine, thereby restoring peripheral and systemic
morphine analgesia.
Adjuvant analgesics include anticonvulsant agents, such as VPA
that potentiates morphine analgesia (14), possibly through inhibi-
tion of gamma-aminobutyric acid (GABA) transaminase. Consid-
ering that VPA at a dose of 200 mg/kg failed to affect morphine
analgesia in sham-operated mice, it is improbable that VPA could
restore morphine analgesia after injury via an increase in GABA
concentration. Alternatively, the present study suggested that VPA
could reduce the dose of morphine required for the management of
neuropathic pain via the restoration of MOP expression in the DRG.
Additionally, VPA has been reported to prevent the development of
analgesic tolerance to morphine through inhibition of glycogen
synthase kinase 3b (15). Collectively, these observations suggest
that VPA has multiple beneﬁts in the treatment of neuropathic pain
with morphine.
In summary, we show here that HDAC inhibitors block injury-
induced MOP down-regulation in the DRG, thereby restoring pe-
ripheral and systemic morphine analgesia. Thus, HDAC inhibitors
might be a novel adjuvant analgesic to morphine for the manage-
ment of neuropathic pain.
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